Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
June 05 2008 - 6:30PM
PR Newswire (US)
SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) will be presenting at the Goldman Sachs Global
Healthcare Conference in Dana Point on Wednesday, June 11, 2008 at
1:20 p.m. PT. Daniel M. Bradbury, President and Chief Executive
Officer of Amylin Pharmaceuticals, will be providing a corporate
overview. The live presentation will be Web cast, and a recording
will be made available following the event. The Web cast and
recording will be accessible through Amylin's corporate Web site,
located at http://www.amylin.com/. To access the live Web cast,
please log on to Amylin's site approximately fifteen minutes prior
to the presentation to register and download any necessary audio
software. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is headquartered in San Diego,
California with over 2,000 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024